KBY Biotech Indexv0.0.34
Search
← Pipeline|DEC-4099

DEC-4099

Phase 3
By Dechra Pharma (EQT)
Source: Trial-derived·Trials: 3
Modality
Bispecific Ab
MOA
JAK1i
Target
VEGF
Pathway
PI3K/AKT
RSVCervical Ca
Development Pipeline
Preclinical
~Aug 2017
→ ~Nov 2018
Phase 1
~Feb 2019
→ ~May 2020
Phase 2
~Aug 2020
→ ~Nov 2021
Phase 3
Feb 2022
→ Sep 2031
Phase 3Current
NCT03636163
2,268 pts·Cervical Ca
2023-10→2031-09·Active
NCT07917628
2,457 pts·RSV
2025-12→2029-06·Not yet recruiting
NCT06938607
2,169 pts·Cervical Ca
2022-02→2030-01·Terminated
6,894 total pts2 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2029-06-043.2y awayPh3 Readout· RSV
2030-01-273.8y awayPh3 Readout· Cervical Ca
2031-09-285.5y awayPh3 Readout· Cervical Ca
Trial Timeline
2022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P3
Termina…
P3
Active
P3
Not yet…
Catalysts
Ph3 Readout
2029-06-04 · 3.2y away
RSV
Ph3 Readout
2030-01-27 · 3.8y away
Cervical Ca
Ph3 Readout
2031-09-28 · 5.5y away
Cervical Ca
ActiveTerminatedNot yet recruiting|StartCompletionToday
Trials (3)
NCTPhaseIndicationStatusNEP
NCT03636163Phase 3Cervical CaActive2268EDSS
NCT07917628Phase 3RSVNot yet recr...2457UPDRS
NCT06938607Phase 3Cervical CaTerminated2169HbA1c
Competitors (10)
DrugCompanyPhaseTargetMOA
JNJ-7458Johnson & JohnsonPhase 1/2PD-1JAK1i
ZanuderotideNovartisPhase 1/2VEGFCD3xCD20
GeliderotideSanofiPhase 1/2PRMT5JAK1i
TAK-8730TakedaPhase 2VEGFFXIai
PexaosocimabDaiichi SankyoPhase 2PD-1JAK1i
GIL-2011Gilead SciencesPreclinicalVEGFSOS1i
BemazumabRegeneronPhase 1VEGFTROP-2 ADC
AdagratapinarofVertex PharmaPreclinicalBCMAJAK1i
ARG-1924ArgenxPreclinicalDLL3JAK1i
PemicapivasertibLegend BiotechPhase 3VEGFCDK4/6i